Advertisement

The Role of the Navigator During a Patient’s Cancer Treatment

  • Linda Burhansstipanov
  • Lillie D. Shockney
Chapter

Abstract

The purpose of this chapter is to provide an overview of the most common types of cancer treatment modalities and to describe the role of navigators on the multidisciplinary treatment team during these phases of care. Patients may receive just one phase of treatment, such as surgery, or may be transitioned through various phases of treatment such as surgery, chemotherapy, radiation, and hormonal therapy. Each phase or treatment requires decision-making, and the navigator serves as a patient advocate and patient educator and promotes the patient’s active participation in the treatment decisions that are being made. Navigators also reassess the patient for any barriers to care; these barriers can change depending on the phase of treatment the patient is receiving at any given time. A description of multi-level barriers, and strategies to address those barriers, is provided. Tables are provided for ease of reference. Several case studies are presented to highlight the role of the navigator throughout treatment. Special attention is given to Native American cancer patients, as well as sexual and gender minorities, two populations often ignored in mainstream patient navigation literature.

Keywords

Cancer treatment Side effects Patient navigation Surgery Chemotherapy Radiation therapy Hormonal therapy Biologic targeted therapy Immunotherapy 

References

  1. 1.
    Willis LA, Reed E, Pratt-Chapman M, Kapp H, Hatcher E, Vaitones V, Collins S, Bires J, Washington E. Development of a framework for patient navigation: delineating roles across navigator types. J Oncol Navig Surviv. 2013;4:20–6.Google Scholar
  2. 2.
    Morra M, Potts E. Choices. New York: Avon Books; 1994.Google Scholar
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
    National Cancer Institute. Immunotherapy. 2017. www.cancer.gov/research/areas/treatment/immunotherapy-using-immune-system.
  15. 15.
    National Cancer Institute. Immunotherapy. 2017. www.cancer.gov/about-cancer/treatment/types/immunotherapy.
  16. 16.
  17. 17.
  18. 18.
  19. 19.
  20. 20.
    Parkinson AJ, Gold BD, Bulkow L, Wainwright RB, Swaminathan B, Khanna B, Peterson KM, Fitzgerald MA. High prevalence of Helicobacter pylori in the Alaska Native Population and Association with low serum ferritin levels in young adults. Clin Diagn Lab Immunol. 2000;7(6):885–8.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Native American Cancer Research CorporationPineUSA
  2. 2.Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations